Genetics

Cesca Therapeutics was awarded a new patent from the US Patent and Trademark Office.

Cesca Therapeutics (NASDAQ:KOOL) was awarded a new patent from the US Patent and Trademark Office (USPTO).
As quoted in the press release:

This new patent covers Cesca’s proprietary method for separating rare, therapeutically critical target cells from blood, bone marrow, leukapheresis product, and other cell sources, while maintaining the viability of the cells under asceptic conditions. This advanced cell separation technology, known as Buoyancy-Activated Cell Separation, or BACS, is key to the ongoing development of Cesca’s CAR-TXpress™ platform.

“As we vigorously pursue our goal of becoming a leading player in the emerging field of personalized medicine, including exciting new immunotherapies such as CAR-T, it is critical that the uniqueness of our innovations are recognized by the USPTO and other global intellectual property regulatory agencies,” said Chris Xu, Cesca’s chief executive officer. “We believe our X-BACS technology, which is key to CAR-TXpress, allows us to address the unique needs of a broad range of potential partners, including CAR-T manufacturers, medical device companies, distributors and academic institutions. We are grateful to the USPTO for granting this latest patent, and we look forward to further strengthening our intellectual property estate in the coming months.”

Click here to read the full press release.

Source: globenewswire.com

MARKETS

Markets
TSX18717.12-286.92
TSXV631.79-9.11
DOW30677.36+194.23
S&P 5003795.730.00
NASD11232.19+179.11
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1822.37-2.05
Silver20.86-0.14
Copper3.71-0.04
Palladium1870.00+30.23
Platinum915.77+5.78
Oil106.51+2.24
Heating Oil4.24+0.02
Natural Gas6.27+0.03

DOWNLOAD FREE REPORTS

×